Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Cora N. Sternberg(Cornell University), Sebastiano Buti(University of Parma), Cinzia Ortega(Candiolo Cancer Institute), Alessandra Bearz(Centro di Riferimento Oncologico), Giacomo Cartenì(Ospedale Antonio Cardarelli), Claudio Verusio(Medica (Italy)), Manfred Mitterer(Krankenhaus Meran), Enrico Mini(University of Florence), Paolo Marchetti(Istituto Dermopatico dell'Immacolata), Francesco Ferraù(Université Paris-Sud), Alessandro Scoppola(Istituto Dermopatico dell'Immacolata), Giuseppe Procopio(Fondazione IRCCS Istituto Nazionale dei Tumori), Claudia Caserta(Inserm), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Giuseppe Fornarini(Ospedale Policlinico San Martino), Umberto Basso(Istituto Oncologico Veneto), Diana Giannarelli(Agostino Gemelli University Polyclinic), Paolo Bidoli(Fondazione IRCCS Istituto Nazionale dei Tumori), Lucio Crinò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori)
Cited by 240
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k